Pacira Story

<div class='circular--portrait' style='background:#1A69FC;color: #ffffff;font-size:4em;'>PP</div>
PCRX -- USA Stock  

USD 62.74  0.77  1.21%

Whilst many millenniums are getting more into healthcare space, it makes sense to break down Pacira Pharm. We will try to explain if it is still possible for Pacira Pharm to generate above-average margins. Is the firm current valuation justified? We will cover Pacira Pharm valuation to give you a better outlook on taking a position in the stock.
Published over a month ago
View all stories for Pacira Pharm | View All Stories
Is Pacira Pharm (NASDAQ:PCRX) ready for a correction?
This firm currently holds 536.37 M in liabilities with Debt to Equity (D/E) ratio of 0.92, which is about average as compared to similar companies.
On a scale of 0 to 100, Pacira Pharm holds a performance score of 10. The company holds a Beta of 0.9074, which implies possible diversification benefits within a given portfolio. Let's try to break down what Pacira's beta means in this case. Pacira Pharm returns are very sensitive to returns on the market. As the market goes up or down, Pacira Pharm is expected to follow. Although it is vital to follow Pacira Pharm current trending patterns, it is good to be conservative about what you can do with the information regarding equity existing price patterns. The philosophy towards forecasting future performance of any stock is to evaluate the business as a whole together with its past performance, including all available fundamental and technical indicators. By analyzing Pacira Pharm technical indicators, you can presently evaluate if the expected return of 0.38% will be sustainable into the future. Please employ Pacira Pharm mean deviation, information ratio, as well as the relationship between the Information Ratio and downside variance to make a quick decision on whether Pacira Pharm historical price patterns will revert.
We determine the current worth of Pacira Pharm using both absolute as well as relative valuation methodologies to arrive at its intrinsic value. In general, an absolute valuation paradigm, as applied to this company, attempts to find the value of Pacira Pharm based exclusively on its fundamental and basic technical indicators. By analyzing Pacira Pharm's financials, quarterly and monthly indicators, and related drivers such as dividends, operating cash flow, and various types of growth rates, we attempt to find the most accurate representation of Pacira Pharm's intrinsic value. In some cases, mostly for established, large-cap companies, we also incorporate more traditional valuation methods such as dividend discount, discounted cash flow, or asset-based models. As compared to an absolute model, our relative valuation model uses a comparative analysis of Pacira Pharm. We calculate exposure to Pacira Pharm's market risk, different technical and fundamental indicators, relevant financial multiples and ratios, and then comparing them to Pacira Pharm's related companies.

Pacira Pharm Investment Alerts

Pacira investment alerts and warnings help investors to get more proficient at understanding not only critical technical and fundamental signals but also the significant portfolio-centered indicators. These indicators include beta, alpha, and other risk-related measures that will help you in monitoring Pacira Pharm performance across your portfolios.Please check all investment alerts for Pacira

Pacira Pharm Valuation Ratios as Compared to Competition

Our valuation model uses many indicators to compare Pacira value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Pacira Pharm competition to find correlations between indicators driving the intrinsic value of Pacira.

What do experts say?

Stock analysis is a method for investors and traders to make buying and selling decisions. By studying and evaluating past and current data, investors and traders attempt to gain an edge in the markets by making informed decisions.
It is good to see analyst projects for Pacira Pharm, but it might be worth checking our own buy vs. sell analysis

Exercise or conversion by Kristen Williams of 63 shares of Pacira Pharm subject to Rule 16b-3

Legal trades by Pacira Pharm insiders are very common, as founders, directors, or employees of any publicly traded firm often have stock or stock options. These trades are made public in the United States through the filing of Form 4 of the Securities and Exchange Commission. Below entry was recorded recently and is publicly available as an insider trade:
Pacira insider trading alert for exercise of stock option (right to buy) by Kristen Williams, Chief Administrative Officer, on 15th of April 2021. This event was filed by Pacira Biosciences Inc with SEC on 2021-04-15. Statement of changes in beneficial ownership - SEC Form 4. Kristen Williams currently serves as chief administrative officer, general counsel, secretary of Pacira Pharm [view details]   
Note, although insider trading is legal, in the United States, Canada, Australia, and Germany, for mandatory reporting purposes, corporate insiders are defined as a company's officers, directors, and any beneficial owners of more than 10% of a class of the company's equity securities.

A Deeper Perspective

The company reported the previous year's revenue of 421.1 M. Net Income was 126.12 M with profit before overhead, payroll, taxes, and interest of 242.19 M.

Margins Breakdown

Pacira profit margins show the degree to which it makes money. Margin indicators are used not only by investors but also by creditors or Pacira Pharm itself as indicators of financial health and management effectiveness. Please look more closely at the different varieties of Pacira Pharm profit margins.
Operating Margin2.42
EBITDA Margin4.5
Gross Margin55.28
Profit Margin(2.54)


Pacira Pharm Revenue Per Employee is increasing over the last 8 years. The previous year's value of Pacira Pharm Revenue Per Employee was 508,159. Further, Pacira Pharm Average Assets is increasing over the last 8 years. The current value of Pacira Pharm Average Assets is 975,742,263.

Are Pacira Pharm technical ratios showing a correction?

Pacira Pharm current maximum drawdown rises over 12.67. Pacira Pharm currently demonstrates below-average downside deviation. It has Information Ratio of 0.08 and Jensen Alpha of 0.22. However, we advise investors to further question Pacira Pharm expected returns to ensure all indicators are consistent with the current outlook about its relatively low value at risk. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Pacira Pharm's stock risk against market volatility during both bullying and bearish trends. The higher level of volatility that comes with bear markets can directly impact Pacira Pharm's stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different stocks as prices fall.

Our Takeaway on Pacira Pharm Investment

While some other firms under the drug manufacturers?specialty & generic industry are still a bit expensive, Pacira Pharm may offer a potential longer-term growth to investors. While some investors may not share our view we believe that the current risk-reward utility is not appealing enough to do any trading. Please use our equity advice module to run different scenarios to ensure your current risk level and investment horizon are fully reflective of your current investing preferences in regards to Pacira Pharm.

About Contributor

This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Vlad Skutelnik do not own shares of Pacira Pharm. Please refer to our Terms of Use for any information regarding our disclosure principles.

Would you like to provide feedback on the content of this article?

You can get in touch with us directly or send us a quick note via email to editors@macroaxis.com